Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

Tumor or target heterogeneity (TH) implies presence of variable cellular populations having different genomic characteristics within the same tumor, or in different tumor sites of the same patient. The challenge is to identify this heterogeneity, as it has emerged as the most common cause of ‘treatm...

Full description

Bibliographic Details
Main Authors: Ameya D Puranik, Clarisse Dromain, Neil Fleshner, Mike Sathekge, Marianne Pavel, Nina Eberhardt, Friedemann Zengerling, Ralf Marienfeld, Michael Grunert, Vikas Prasad
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
heterogeneity
Prostate Cancer
neuroendocrine tumor
PSMA
Ga-68
PET/CT
Online Access:https://www.mdpi.com/2072-6694/13/14/3607

Similar Items

Similar Items